Business Inquiry
Global:
Email:marketing@medicilon.com
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone. GLP-1 exists in two equally bioactive forms, GLP-1 (7-37) amide and GLP-1 (7-36) amide. GLP-1 is a biological product derived from the post-translational processing of proglucagon. GLP-1 is secreted by the enteroendocrine L cells, but also by some neuronal populations in the hindbrain. GLP-1 potentiates insulin release and reduces glucagon’s concentration in physiological conditions.
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA,1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.